SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash TEL AVIV, Israel, Aug. 28,...

Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries Polyrizon will be entitled for up to $3.35 million in addition to future royalties Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged...

Medigus: Eventer Signs Agreements with Two Teams from the Israeli Basketball Premier League and the Israeli National Basketball League Eventer will leverage its capabilities in the sports sector and intends to expand its outreach to leagues in the US and Europe Tel Aviv, Israel, July 01, 2022 (GLOBE NEWSWIRE) --  Medigus...

SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology TEL AVIV, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....